Diabetic Foot Consortium – One Year Extension

May 2020 Council

Lead Division/Office


Point(s) of Contact

Henry Burch, M.D.; Teresa Jones, M.D.

Executive Summary

Foot ulcers are a common and costly complication of diabetes that burdens patients and their families with lengthy and often unsuccessful treatments that frequently result in a lower extremity amputation. The NIDDK Diabetic Foot Consortium (DFC) was established in September 2018 with the mission of validating biomarkers for diabetic foot ulcers and building a clinical research infrastructure with the long-range goal of rigorously testing new therapies to improve diabetic wound healing and prevent amputations. The DFC consists of a data coordinating center, six clinical research units and two biomarker analysis units and will start recruitment for two biomarker clinical studies in Spring 2020. This request is for a one-year extension of the DFC through FY 2022 with the anticipation that a full five-year renewal and possible expansion will be requested starting in FY 2023.